Close Menu

NEW YORK (GenomeWeb) – Microbial genetics analysis firm OpGen plans to offer 3.75 million shares of its common stock for its planned initial public offering, the company said in an amended Form S-1 today. 

The company said that it plans to offer its stock at a price between $8 and $10 per share. At the midpoint price of $9, OpGen anticipates the IPO will bring in net proceeds of about $30.5 million, or $35.2 million if the offering's underwriter exercises its overallotment option in full. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.

Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research. 

Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.

In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.